The Australia and New Zealand Dialysis and Transplant Registry (ANZDATA) records the incidence, prevalence and outcomes of dialysis and transplant treatment for paƟents with end‐stage kidney disease Data on chronic dialysis and transplantaƟon Indicators of clinical process Outcome Data COLLECTS Outcome of treatment Individual Hospital acƟvity Australian and New Zealand data REPORTS For widespread use of its data for Quality Assurance, Audits, Surveys, Service Planning and Research Projects PROVIDES 2013 summary ‐ data to 31 December 2012 Transplant outcomes in Australia and New Zea‐ land are excellent, and geƫng even beƩer over Ɵme. In the above graph, graŌ failure includes 0 200 400 600 Number of transplants 2008 2009 2010 2011 2012 Australia 2008-2012 Living and deceased donor transplants Living donor Deceased donor 0.00 0.25 0.50 0.75 1.00 Graft Survival 0 5 10 15 20 Years 2008-2012 (2537) 2003-2007 (1789) 1998-2002 (1777) 1993-1997 (1824) Australia and New Zealand 1993-2012 Primary deceased donor graft survival TRANSPLANTATION The majority of transplants performed in Australia are from deceased donors. In recent years there has been a large increase in deceased donor rates. The majority of this increase is from donors aŌer circulatory death (DCD). Conversely, living donor rates fell over the period 2008‐12. 2013 summary ‐ data to 31 December 2012 c/‐ Royal Adelaide Hospital North Terrace Adelaide South Australia Phone: +61 8 8222 0951 Fax: +61 8 8222 0985 Email: [email protected]Website; www.anzdata.org.au CONTACT US PUBLICATIONS ANZDATA is the source of a large number of scienƟfic and other publicaƟons. Some select‐ ed recent publicaƟons are listed here. A more complete list is available on our website. Pregnancy outcomes for kidney trans‐ plant recipients.Wyld ML, et al. Am J Transplant. 2013 Pregnancy Outcomes According to Dialy‐ sis Commencing Before or AŌer Concep‐ Ɵon in Women with ESRD.Jesudason S, et al. Clin J Am Soc Nephrol. 2013 Cytomegalovirus & Epstein Barr Vi‐ rus Serostatus as a predictor of the long term Outcome of Kidney Transplanta‐ Ɵon.Le Page AK, et al. Nephrology (Carlton). 2013 Post‐transplant lymphoproliferaƟve dis‐ order: no relaƟonship to recombinant human growth hormone use in Australian and New Zealand pediatric kidney trans‐ plant recipients.Longmore DK, et al. Pedi‐ atr Transplant. 2013 v 2013
Transcript
The Australia and New Zealand Dialysis and Transplant Registry (ANZDATA) records the incidence, prevalence and outcomes of dialysis and transplant treatment for pa ents with end‐stage
kidney disease
Data on chronic dialysis and transplanta on Indicators of clinical process
Outcome Data
COLLECTS
Outcome of treatment Individual Hospital ac vity
Australian and New Zealand data
REPORTS
For widespread use of its data for Quality Assurance, Audits, Surveys,
Service Planning and Research Projects
PROVIDES
2013 summary ‐ data to 31 December 2012
Transplant outcomes in Australia and New Zea‐land are excellent, and ge ng even be er over
me. In the above graph, gra failure includes
020
040
060
0N
umbe
r of t
rans
plan
ts
2008 2009 2010 2011 2012
Australia 2008-2012Living and deceased donor transplants
Australia and New Zealand 1993-2012Primary deceased donor graft survival
TRANSPLANTATION
The majority of transplants performed in Australia are from deceased donors. In recent years there has been a large increase in deceased donor rates. The majority of this increase is from donors a er circulatory death (DCD). Conversely, living donor rates fell over the period 2008‐12.
PUBLICATIONS ANZDATA is the source of a large number of scien fic and other publica ons. Some select‐ed recent publica ons are listed here. A more complete list is available on our website. Pregnancy outcomes for kidney trans‐
plant recipients.Wyld ML, et al. Am J Transplant. 2013
Pregnancy Outcomes According to Dialy‐sis Commencing Before or A er Concep‐
on in Women with ESRD.Jesudason S, et al. Clin J Am Soc Nephrol. 2013
Cytomegalovirus & Epstein Barr Vi‐rus Serostatus as a predictor of the long term Outcome of Kidney Transplanta‐
on.Le Page AK, et al. Nephrology (Carlton). 2013
Post‐transplant lymphoprolifera ve dis‐order: no rela onship to recombinant human growth hormone use in Australian and New Zealand pediatric kidney trans‐plant recipients.Longmore DK, et al. Pedi‐atr Transplant. 2013
v2013
2013 summary ‐ data to 31 December 2012 2013 summary ‐ data to 31 December 2012 2013 summary ‐ data to 31 December 2012
010
020
030
040
050
060
0N
ew p
atie
nts
per m
illio
n po
pula
tion
2003 2004 2005 2006 2007 2008 2009 2010 2011 2012
Australia indigenous New Zealand indigenousAustralia non-indigenous New Zealand non-indigenous
New patients 2003-2012
Australia New Zealand
PD Home HD Other HD
31 December 2012Dialysis modality by country
Australia Total 20,766 (919)
No. Functioning Transplants 9,320 (413)
No. Dialysis Patients 11,446 (507) Proportion Home 29% Proportion Satellite HD 49%
Australia and New Zealand 2001-2012Censored for transplant
Technique survival - peritoneal dialysis at 90 days
020
4060
8010
0P
erce
nt
0 20 40 60Caring hospital
Excludes hospitals with <10 patients
Australia and New Zealand 2012% New HD patients starting with AVF/AVG
At the end of 2012 there were just under 21,000 pa ents receiving renal replacement therapy in Australia and nearly 4,000 in NZ.
Australia and New Zealand have a strong focus on home dialysis, with 29% of Australian and 50% of New Zealand dialysis pa ents receiving dialysis at home.
PREVALENT PATIENTS
This brochure provides an introduc on to ANZDATA and includes data collected to the end of 2012, and reported in the 2013 Annual Re‐port. The ANZDATA Registry collects informa on on renal replacement therapy (dialysis and transplanta on) for end‐stage kidney disease in Australia and New Zealand. Much more informa on can be found at our website, including our Annual Report, data forms and dic onaries, list of publica ons and guidelines for reques ng data.
There were 2534 pa ents who commenced treatment for end‐stage renal failure in Australia in 2011, a rate of 112 per million popula on. In New Zealand, the number of new pa ents com‐mencing renal replacement treatment was 513, a rate of 116 per million of popula on. Rates of treated end‐stage kidney disease are substan ally higher in Indigenous than non‐Indigenous popula ons in both Australia and New Zealand.
INTRODUCTION
NEW PATIENTS
DIALYSIS
ANZDATA has been repor ng real‐ me and annual “key process indicators” (KPIs) for haemodialysis (HD) and peritoneal dialysis (PD) since 2011. At present for HD we report the propor on of new pa ents star ng HD with a fistula or gra . There is a large varia on between trea ng hospitals.
A rela vely large propor on of dialysis pa ents in Australia and New Zealand use PD. The main rea‐sons for technique failure are pa ent preference, infec ve complica ons and death.
